Decibel Therapeutics Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Laurence Reid

Chief Executive Officer (CEO)

US$1.2m

Compensación total

Porcentaje del salario del CEO	44.5%
Permanencia del CEO	3.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	2.4yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Aug 10

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Feb 07

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Oct 17

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Sep 01

Decibel Therapeutics: Gene Therapies For Hearing Loss

Jul 06

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Laurence Reid en comparación con los beneficios de Decibel Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	-US$63m
Mar 31 2023	n/a	n/a	-US$62m
Dec 31 2022	US$1m	US$548k	-US$63m
Sep 30 2022	n/a	n/a	-US$60m
Jun 30 2022	n/a	n/a	-US$60m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$801k	US$522k	-US$54m
Sep 30 2021	n/a	n/a	US$576k
Jun 30 2021	n/a	n/a	US$7m
Mar 31 2021	n/a	n/a	US$8m
Dec 31 2020	US$4m	US$574k	US$7m

Compensación vs. Mercado: La compensación total de Laurence($USD1.23M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.63K).

Compensación vs. Ingresos: La compensación de Laurence ha aumentado mientras la empresa no es rentable.

CEO

Laurence Reid (59 yo)

3.8yrs

Permanencia

US$1,232,276

Compensación

Dr. Laurence E. Reid, Ph D., serves as President, Chief Executive Officer and until September 25, 2023 served as Director at Decibel Therapeutics, Inc. since January 2020 and served as its consultant since...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Laurence Reid	President & CEO	3.8yrs	US$1.23m	sin datos
Anna Trask	Executive VP & Chief People Officer	5.8yrs	US$618.23k	0% $ 0
John Lee	Executive VP & Chief Development Officer	7.1yrs	US$733.16k	0% $ 0
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
James Murphy	Interim CFO	less than a year	sin datos	sin datos
Elaine Cope	Vice President of Operations	2.1yrs	sin datos	sin datos
Geoff Horwitz	VP of Corporate Development & Head of Business Development	less than a year	sin datos	sin datos
Vassili Valayannopoulos	VP and Head of Clinical Research & Development	less than a year	sin datos	sin datos

2.1yrs

Permanencia media

65yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de DBTX se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Glenn Pierce	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Constance Cepko	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Guangping Gao	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Alan Cheng	Member of Scientific Advisory Board	no data	sin datos	sin datos
David Ginty	Member of Scientific Advisory Board	no data	sin datos	sin datos
Michael Greenberg	Member of Scientific Advisory Board	no data	sin datos	sin datos
Dwight Bergles	Member of Scientific Advisory Board	no data	sin datos	sin datos
Matthew Kelley	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos

2.4yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de DBTX no se considera experimentada (2.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Decibel Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Decibel Therapeutics, Inc. Announces Board Changes

High number of new directors

High number of new directors

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics, Inc. Announces Executive Changes

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Recent updates

Decibel Therapeutics, Inc. Files Form 15

New major risk - Revenue and earnings growth

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index

Decibel Therapeutics, Inc. Announces Board Changes

Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders for approximately $100 million.

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Price target increased by 13% to US$15.33

Consensus EPS estimates upgraded to US$1.89 loss

Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to Initiate Clinical Development of Lead Gene Therapy Candidate Db-OTO

Price target decreased by 7.4% to US$12.60

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

PDecibel Therapeutics, Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

Consensus revenue estimates fall by 25%

High number of new directors

Decibel Therapeutics, Inc. Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate Db-Oto

High number of new directors

Price target decreased to US$14.60

Decibel Therapeutics, Inc. Receives Fda Clearance of Ind Application for Db-Oto, A Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

Decibel Therapeutics, Inc. Announces Executive Changes

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Price target decreased to US$15.40

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

Price target decreased to US$14.75

Consensus forecasts updated

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$17.00

Less than half of directors are independent

Price target decreased to US$21.33

Decibel Therapeutics Announces the Presentation of Preclinical Data on Lead Gene Therapy Product Candidate, DB-OTO and Preclinical Data Highlighting the Identification of Proprietary

Less than half of directors are independent

Chief People notifies of intention to sell stock

President recently bought US$76k worth of stock

Vice President of Finance & Principal Accounting Officer Ronald Vigliotta has left the company

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$2.08m

Investor sentiment deteriorated over the past week

Decibel Therapeutics: Gene Therapies For Hearing Loss

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from Russell Microcap Growth Index

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Decibel Therapeutics, Inc. Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations

Decibel Therapeutics, Inc. has completed an IPO in the amount of $127.116 million.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad